EcoDrugPlus

24-Dehydrocholesterol Reductase

Ensembl ID : ENSMNEG00000041545
Gene Symbol: DHCR24
4 Cross references
208 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

26s Proteasome Regulatory Subunit 4-Like

Ensembl ID : ENSMNEG00000030103
Gene Symbol: LOC105492274
1 Cross references
169 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

3-Hydroxy-3-Methylglutaryl-Coa Reductase

Ensembl ID : ENSMNEG00000036782
Gene Symbol: HMGCR
4 Cross references
270 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

4-Hydroxyphenylpyruvate Dioxygenase

Ensembl ID : ENSMNEG00000030703
Gene Symbol: HPD
4 Cross references
204 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

40s Ribosomal Protein S12

Ensembl ID : ENSMNEG00000011928
Gene Symbol: LOC105496576
2 Cross references
136 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

40s Ribosomal Protein S12 Pseudogene

Ensembl ID : ENSMNEG00000025322
Gene Symbol: LOC105479970
1 Cross references
140 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

40s Ribosomal Protein S13 Pseudogene

Ensembl ID : ENSMNEG00000009507
Gene Symbol: LOC105481433
1 Cross references
118 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

40s Ribosomal Protein S15 Pseudogene

Ensembl ID : ENSMNEG00000035375
Gene Symbol: LOC105479172
1 Cross references
154 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

40s Ribosomal Protein S15 Pseudogene

Ensembl ID : ENSMNEG00000030988
Gene Symbol: LOC105480831
1 Cross references
159 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

40s Ribosomal Protein S20 Pseudogene

Ensembl ID : ENSMNEG00000019715
Gene Symbol: LOC105484174
1 Cross references
158 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

40s Ribosomal Protein S21

Ensembl ID : ENSMNEG00000028050
Gene Symbol: LOC105496008
3 Cross references
151 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

40s Ribosomal Protein S24 Pseudogene

Ensembl ID : ENSMNEG00000017308
Gene Symbol: LOC105476750
1 Cross references
162 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).